(Q37686896)

22 August 2017

1 reference

title

Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinoma (English)

1 reference

22 August 2017

0 references

Sosman JA

1

1 reference

22 August 2017

Hank JA

2

1 reference

22 August 2017

Moore KH

3

1 reference

22 August 2017

Borchert A

4

1 reference

22 August 2017

Schell K

5

1 reference

22 August 2017

Kohler PC

6

1 reference

22 August 2017

Goldstein D

7

1 reference

22 August 2017

Bechhofer R

8

1 reference

22 August 2017

Storer B

9

1 reference

22 August 2017

Albertini MR

10

1 reference

22 August 2017

publication date

1 January 1991

1 reference

22 August 2017

1 reference

22 August 2017

volume

9

1 reference

22 August 2017

issue

1

1 reference

22 August 2017

page(s)

35-48

1 reference

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F07357909109032798

Interleukin-2: inception, impact, and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109032798

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109032798

Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109032798

Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109032798

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109032798

Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109032798

Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109032798

Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109032798

Adoptive immunotherapy for stage IV renal cell carcinoma: a novel protocol utilizing periodate and interleukin-2-activated autologous leukocytes and continuous infusions of low-dose interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109032798

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109032798

Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109032798

Phase II trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic leukemia, and selected solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109032798

A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109032798

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109032798

Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer-associated antigens, NKH1A and NKH2, expressed on subsets of large granular lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109032798

Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109032798

Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109032798

NIH conference. New approaches to the immunotherapy of cancer using interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109032798

On lymphokines, cytokines, and breakthroughs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109032798

Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109032798

Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109032798

Murine interleukin-4 displays potent anti-tumor activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109032798

10.3109/07357909109032798

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference